Dr. Leighl continued her presentation on "Highlights in Lung Cancer, 2012" with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a "driver mutation" like an EGFR mutation or an ALK rearrangement.

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

[powerpress]